Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.98 estudios en Gastroenterología y Hepatología (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. Prospective Tissue Collection of Hepatic Epithelia: Rochester, Minn. The purpose of this research study is to improve our understanding of normal liver and gallbladder function and liver and gallbladder diseases including PBC, PSC, ADPKD (Autosomal Dominant Polycystic Kidney Disease), and ARPKD (Autosomal Recessive Polycystic Kidney Disease) and gallbladder inflammation (cholecystitis). Interviews About Social Determinants of Health in Southeast Asian Americans to Identify Liver Cancer Disparities Rochester, Minn. This study is intended to understand the experiences and barriers to cancer care for individuals diagnosed with liver or any other type of cancer. Individual interviews will be conducted. Fecal Microbiota Transplant National Registry Rochester, Minn. A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness. A Study of Measurable Ultrasound Imaging Biomarkers of Crohn's Disease Rochester, Minn. The purpose of this study is to assess the effectiveness of a new multi-parameter ultrasound technology for evaluation of Crohn’s disease. A Study to Assess Outcome of Hospitalization for Cirrhosis Patients Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the outcome of hospitalization related to the presence of cirrhosis. We are participating in optional blood, saliva, urine, ascitic fluid and stool collection. Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients Scottsdale/Phoenix, Ariz., Rochester, Minn. This is a phase II multi-center study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable pancreatic cancer patients. DISEASE STATE - Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed. - Staging by pancreatic protocol, helical abdominal computed tomography (with contrast) or MRI (with contrast) required (endoscopic ultrasound is not required). - No evidence of metastatic disease. Lymphadenopathy (defined as nodes measuring >1 cm in short axis) outside the surgical basin (i.e., para-aortic, peri-caval, celiac axis, or distant nodes) is considered M1 (unless nodes are biopsied and are negative, then enrollment can be considered after review with the study PI). Potentially Resectable Pancreatic Cancer - No involvement of the celiac artery, common hepatic artery, and superior mesenteric artery (SMA) and, if present, replaced right hepatic artery. - No involvement or <180° interface between tumor and vessel wall of the portal vein and/or superior mesenteric vein (SMV-PV) and patent portal vein/splenic vein confluence. - For tumors of the body and tail of the pancreas, involvement of the splenic artery and vein of any degree is considered resectable disease. Borderline Resectable Pancreatic Cancer - Tumor-vessel interface ≥180° of vessel wall circumference, and/or reconstructible occlusion of the SMV-PV. - Tumor-vessel interface <180° of the circumference of the SMA. - Tumor-vessel interface <180° of the circumference of the celiac artery. - Reconstructible short-segment interface of any degree between tumor and hepatic artery. Evaluation of Outcomes in Metastatic Gastric and Esophageal Carcinoma in Relation to Immunotherapy Rochester, Minn. The purpose of this study is: To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal carcinoma through retrospective chart review. To explore if response to checkpoint inhibitors is dependent on biomarkers on tumor tissue. A Study of a New Molecular Approach to Blood DNA Screening for Cancer Rochester, Minn. The primary aim of this study is to evaluate the distribution of marker levels determined by this multi-marker, multi-compartment blood DNA test approach across persons without known cancer or precancer. A Study of Sonidegib and Pembrolizumab in Advanced Solid Tumors Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the maximum tolerated dose (MTD) of sonidegib in combination with pembrolizumab in participants with advanced solid tumors as part of the dose escalation phase, and to estimate the response rate of sonidegib in combination with pembrolizumab in participants with NSCLC or pancreas cancer as part of the expansion cohort based on RECIST criteria. A Study to Evaluate Smartphone-based Digital Phenotyping for Relapse Prediction in Alcohol-associated Liver Disease Rochester, Minn. The primary aim of this study is to define a comprehensive digital phenotype that predicts risk for near-future relapse or relapse in alcohol use in patients with alcohol-associated liver disease. The secondary aim of this study is to assess the relationship between this digital phenotype and markers of disease severity outcome, including MELD score and readmission rates. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 11 Ir a página 22 Ir a página 33 Ir a página 44 Ir a página 55 SiguientePróxima página Solicite una consulta Conocimientos y categoríasInvestigación May 30, 2024 Comparte en: FacebookTwitter U.S. News & World Report reconoce a Mayo Clinic de Rochester, Minnesota, como el mejor hospital del país para gastroenterología y cirugía gastrointestinal en el período 2024-2025. Obtén más información sobre este gran honor Gastroenterología y HepatologíaPágina inicialdel departamentoSeccionesPanorama generalAnálisis y procedimientosEnfermedades tratadasMédicosMédicos por sede y especialidadGrupos por especialidadConocimientos y categoríasEnsayos clínicosInvestigaciónHistorias de pacientesCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaPanorama generalMédicosMédicos por sede y especialidadGrupos por especialidadConocimientos y categoríasInvestigaciónCostos y seguroRemisiones ORG-20308333 Centros y departamentos médicos Gastroenterología y Hepatología